Navigation Links
Plandai Biotechnology, Inc. Announces Shipment Of First Machinery To South African Production Facility
Date:4/24/2013

SEATTLE, April 24, 2013 /PRNewswire/ -- Plandai Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced arrival of the first shipment of factory equipment to its production facility in South Africa.  The processing line will be used in the Company's proprietary extraction process, which produces botanicals with a higher degree of bioavailability than other botanical phytonutrients on the market.

Installation, calibration and testing of the equipment is expected by August with the processing and extraction facility expected to be ready for the first harvest in November 2013. 

"Shipment of this equipment is an important first step in the ramping up of production at our production facility in South Africa," said Roger Duffield , Chairman and Chief Executive Officer of Plandai Biotechnology.  "With distribution agreements already in place, we are looking forward to increased production as levels of tea leaf harvesting increases." 

Plandai Biotechnology, through its wholly owned subsidiaries, farms over 7,500 acres of luscious land in the Mpumalanga province of South Africa.  The Company is currently farming 1,000 acres of tea bushes, increasing to 2,200 acres over the next five years. 

In published USDA studies, Plandai's proprietary plant extracts, including Phytofare™ Catechin Extract, Phytofare™ Glucoside Complex and Phytofare™ Carotenoid Extract, have shown to have improved bioavailability – the degree to which a substance becomes available to the target tissue after administration – of between 60-80%, far exceeding anything available today.  Superior levels of bioavailability simply mean that the body can actually receive the benefits promised on the product label.

The Company believes that its technology is the foundation for creating an entirely new family of botanical drugs that can treat a multitude of diseases and conditions safely and affordably using naturally-derived extracts. 

About Plandai Biotechnology, Inc.

Plandai Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions.  Plandai Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its patented Phytofare™ extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process.  Targeted industries for the Company's products include beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical.  For more information, please visit http://www.plandaibiotech.com.

Safe Harbor Statement

The information provided may contain forward-looking statements and involve risks and uncertainties. Results, events and performances could vary from those contemplated. These statements involve risks and uncertainties which may cause actual results, expressed or implied, to differ from predicted outcomes. Risks and uncertainties include product demand, market competition, and Plandai's ability to meet current or future plans. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Plandai is not obliged to publicly release revisions to any forward-looking statement, to reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws.

Contact:
Andrew Beyer
Phone: 619-202-7456
Email:  investor@Plandaibiotech.com


'/>"/>
SOURCE Plandai Biotechnology, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Plandai Biotechnology, Inc. Enters Into License Agreement With Phyto Nutricare To Develop Nutraceutical Products
2. Plandai Biotechnology, Inc. Updates Progress Of Preparing Products For Market
3. DuPont Pioneer and Mendel Biotechnology, Inc. Collaborate to Improve Water Use Efficiency and Photosynthesis in Corn
4. White Mountain Process Announces Sanitary Autoclave Style Pharmaceutical Agitator
5. InstantGMP Announces Release of Unique Electronic Batch Record Software as a Service for Just $99/mo
6. Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.
7. Medrio, a Leading EDC and eClinical SaaS Provider for Clinical Research, Announces the Highly Anticipated Release of Medrio 8.1 with iPad Support
8. SPIE Announces 2013 Award Winners
9. MiMedx Group, Inc. Announces Listing on the NASDAQ Capital Market
10. iBio, Inc. Announces Proposed Public Offering
11. California Healthcare Institute Announces Executive Promotion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Financial Highlights (in ... Months Ended December 31,Twelve Months Ended December 31,20162015% ... $           300$     ... Revenue 3539(10)%9498(4)%Kuvan Net Product Revenue ... 756025%297303(2)%Vimizim Net Product Revenue ...
(Date:2/23/2017)... - The Fight Against Cancer Innovation Trust (FACIT) and ... to report that Fusion Pharmaceuticals Inc. (Fusion) has closed ... Innovation – JJDC, Inc. (JJDC) as the lead investor. ... Partners, and Genesys Capital, as well as founding investor ... ...
(Date:2/23/2017)... 23, 2017  In Atlanta, it seems everyone has a ... intertwine to create an expressive and dynamic community unlike any ... and contribute to it. With their newest ... seeks to carry on that tradition with a unique, ... salon is the newest of 13 nationwide locations, ...
(Date:2/23/2017)... Minn. , Feb. 23, 2017  Imanis ... new product line of oncolytic vaccinia viruses for ... Corporation as part of Genelux,s proprietary, vaccinia virus-based ... are excited to enter into a partnership with ... selected oncolytic vaccinia viruses for use in research," ...
Breaking Biology Technology:
(Date:2/3/2017)... , Feb. 3, 2017  Texas Biomedical Research Institute ... Larry Schlesinger as the Institute,s new President ... Biomed effective May 31, 2017. He is currently the Chair ... of the Center for Microbial Interface Biology at Ohio State ... as the new President and CEO of Texas Biomed," said ...
(Date:2/2/2017)... , Feb. 1, 2017  Central to its ... meaningful advances worldwide, The Japan Prize Foundation today ... who have pushed the envelope in their respective ... Communication. Three scientists are being recognized with the ... that not only contribute to the advancement of ...
(Date:1/26/2017)... Jan. 26, 2017  Crossmatch, a leading provider of ... solution aimed at combatting fraud, waste and abuse in ... at the Action on Disaster Relief conference in ... for UN agencies and foreign assistance organizations throughout ... and abuse are a largely unacknowledged problem in the ...
Breaking Biology News(10 mins):